Myelodysplastic Syndromes

Latest News
July 11th 2025

Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 10th 2025

FDA Releases Draft Guidance for MDS Drug Development

July 1st 2025

Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

June 18th 2025

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Video Interviews
View All
July 17th 2025

Imetelstat Linked to Sustained Health-Related Quality-of-Life Benefits in Lower-Risk MDS: María Díez Campelo, MD, PhD

July 16th 2025

Evaluating Imetelstat's Impact on Health-Related Quality of Life in Lower-Risk MDS: María Díez Campelo, MD, PhD

April 2nd 2025

Orca-T Shows Efficacy, Reduced GVHD Risk in Acute Leukemia, MDS: Caspian Oliai, MD

February 7th 2025

Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS

February 6th 2025

Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS

March 17th 2024

Dr Jennifer Vaughn: We Can Provide Aggressive, Effective Treatment, but Help Patients Maintain Quality of Life

February 3rd 2023

Treatment Patterns in the Management of MDS

January 27th 2023

Treatment Paradigm in Lower-Risk MDS (LR-MDS) Patients

January 20th 2023

TP53 Mutation and Its Impact on Patient Outcomes in MDS

December 29th 2022

Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS

More News

Genetic testing for hereditary forms of solid tumors led to an unsuspected diagnosis of MDS, a recent case report described. | Image Credit: Dr_Microbe - stock.adobe.com
May 29th 2025

Genetic Testing for Hereditary Cancer Identifies Case of MDS

Rose McNulty
Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need for careful interpretation of results and multidisciplinary collaboration.
Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com
May 22nd 2025

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

Rose McNulty
Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.
Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
May 16th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Courtney Flaherty
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Patients with LR-MDS, particularly those with the highest rates of infection-related deaths, would benefit from close monitoring for infections. | Image credit: Saiful52 - stock.adobe.com
April 30th 2025

Infection Linked With Nearly a Quarter of Deaths in Lower-Risk MDS

Rose McNulty
Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant monitoring and preventive strategies.
Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
April 25th 2025

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

Rose McNulty
Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
March 28th 2025

ESA Treatment Improves OS in Lower-Risk MDS

Rose McNulty
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.
A newly developed MDS scoring system has similar diagnostic accuracy to a more established, but also more elaborate, system, a new study found. | Image credit: syahrir - stock.adobe.com
March 26th 2025

ELN Scoring System Shows Similar Accuracy to iFS for MDS Diagnosis

Jared Kaltwasser
The European LeukemiaNet (ELN) scoring system showed similar results to the more complicated Integrated Flow Score (iFS) for diagnosing myelodysplastic syndrome (MDS), including in low-risk patients.
Orca-T is manufactured with highly purified regulatory T cells, hematopoietic stem cells, and conventional T cells from peripheral blood from matched donors. | Image credit: fotogurmespb - stock.adobe.com.jpg
March 20th 2025

Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS

Rose McNulty
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies.
In patients with MDS and AML, the researchers found impaired neutrophil subset distribution compared with healthy individuals. | Image credit: keetazalay - stock.adobe.com
March 14th 2025

Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML

Rose McNulty
The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density neutrophil subsets in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and idiopathic cytopenia of unknown significance.
A 1-year interim analysis of the ACROBAT study found AlloHeme accurate and sensitive for monitoring relapse after allo-HSCT in AML and MDS. | Image credit: Елена Бутусова - stock.adobe.com
February 21st 2025

NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS

Rose McNulty
The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
FDA Approval | Image credit: wladimir1804 - stock.adobe.com
February 19th 2025

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths

Rose McNulty
The FDA approved Amneal Pharmaceuticals' generic lenalidomide capsules, referencing Celgene's Revlimid, in multiple strengths.
MDS blood test | Image credit: MdBabul - stock.adobe.com
January 29th 2025

Characterizing Patients With MDS Who Undergo Allo-HSCT

Karen Jacobson-Sive
Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to posters presented at the 2024 American Society of Hematology meeting.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

Rose McNulty
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Two abstracts presented at ASH 2024 provided insight into MDS response to hypomethylating agents (HMAs) | Image credit: Sviatlana - stock.adobe.com
January 19th 2025

Exploring Response to HMAs for MDS Across Various Patient Types

AJMC Contributor
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs).
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
MDS blood test | Image credit: MdBabul - stock.adobe.com
January 13th 2025

Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS

AJMC Contributor
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com
January 6th 2025

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

Kimberly Rath, PharmD
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Nicole Gieselhuber, MD, PhD | Image credit: Ohio State University
January 2nd 2025

Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study

Mary Caffrey Nicole Grieselhuber, MD, PhD
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Top 5 MDS articles of 2024
December 30th 2024

Top 5 Most-Read MDS Content of 2024

Christina Mattina
This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors for progression, and more.
MDS graphic | Image Credit: © Sviatlana-stock.adobe.com
December 18th 2024

Luspatercept Promising Against Anemia in MDS

Kimberly Rath, PharmD
Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
MDS | Image Credit: © ibreakstock-stock.adobe.com
December 11th 2024

Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

Karen Jacobson-Sive
Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.
Visualization of myelodysplastic syndromes | image credit: Lily - stock.adobe.com
December 11th 2024

Additional Hematopoietic Malignancy Predispositions Accounted for in Updated Surveillance Recommendations

AJMC Contributor
The recommendations for surveillance account for newly identified hematopoietic malignancy predispositions (HMP) and HMP genes, as well as a greater understanding of the prevalence of germline variants putting children as an increased risk of MDS and other HMs.
Child in hospital looking out window | Image credit: MIA Studio - stock.adobe.com
November 29th 2024

Survivors of Childhood Cancer at 9-Fold Greater Risk for Late Subsequent Leukemia 

Karen Jacobson-Sive
High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of developing late subsequent leukemia.
MDS wooden blocks held by hand in glove | Image Credit: © Sviatlana - stock.adobe.com
November 27th 2024

Venetoclax May Be an Option for Children With R/R AML, MDS

Jared Kaltwasser
The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Pediatrician test results tablet parent child | Image Credit: © nimito - stock.adobe.com
November 11th 2024

Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition

Karen Jacobson-Sive
Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, according to researchers.
stem cells | Image Credit: © jarun011 -stock.adobe.com
November 8th 2024

Study Explores Radiation-Free Transplant Approach for Patients With Dyskeratosis Congenita

Kimberly Rath, PharmD
A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing allogeneic hematopoietic cell transplantation did not negatively affect survival or increase complications.
Blood cells from blood marrow biopsy | image credit: Катерина Євтехова - stock.adobe.com
November 2nd 2024

Patients With MDS Disagree With Physicians About Symptom Frequency

Jared Kaltwasser
Physicians also differed from caregivers when asked how many hours of caregiving patients required each week.
Myeloid malignancy concept, blood cells floating | image credit: Eleni - stock.adobe.com
October 18th 2024

Phase 1b/2 Study Supports Use of Telaglenastat and Azacytidine in Advanced MDS

Kimberly Rath, PharmD
A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results.
Cancer cells | Image credit: Sodapeaw - stock.adobe.com
October 11th 2024

In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment

Jared Kaltwasser
The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).
123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo